Clinical trials: Rectal Cancer, Radiotherapy
Metastatic Colorectal Cancer
Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis
Metastatic colorectal cancer is one of the common malignant tumors and the overall prognosis is poor. The introduction of immune-checkpoint inhibition (ICI) has led to a paradigm shift in the treatment of patients with metastatic…
- Trial name
- NCT03927898
- Testing
- Toripalimab, Stereotactic Body Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Chinese Academy of Medical Sciences
Locally Advanced Rectal Cancer
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
To explore the complete response (CR) rate of modified short-course radiotherapy plus CAPOX and Tislelizumab versus Long-course Chemoradiotherapy plus Tislelizumab for locally advanced rectal cancer.
- Trial name
- NCT07469306
- Testing
- Modified Short-course radiotherapy, Long-course radiotherapy, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fujian Cancer Hospital
Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
Phase I trial to study the effectiveness of radiation therapy plus chemotherapy followed by surgery and additional chemotherapy in treating patients who have advanced nonmetastatic primary cancer of the rectum.
- Conditions
- Adenocarcinoma of the Rectum, Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer
- Trial name
- NCT00003799
- Testing
- fluorouracil, oxaliplatin, radiation therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Neoplasms, Neoadjuvant Treatment
Preoperative Chemoradiotherapy With Cetuximab in Rectal Cancer
This study is to estimate the pathologic complete response rate of cetuximab, irinotecan, and capecitabine concurrent with radiotherapy given preoperatively in patients with resectable rectal cancer.
- Trial name
- ERBIRIX (NCT00506844)
- Testing
- Cetuximab, Irinotecan, Capecitabine
- Where
- 4 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- National Cancer Center, Korea
Colorectal Cancer
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
RATIONALE: Monoclonal antibodies such as cetuximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00084773
- Testing
- cetuximab, fluorouracil, neoadjuvant therapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Colorectal Cancer
Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Breast Cancer, Colorectal Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00553683
- Testing
- cyclophosphamide, poly ICLC, hepatic artery embolization
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Rutgers, The State University of New Jersey
Rectal Neoplasms, Adenocarcinoma
Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer
A phase II, randomized study of placebo versus metformin in association to chemotherapy with capecitabine and radiation in the neoadjuvant treatment of locally advanced (T3-4N0M0 or TxN1-2M0) rectal carcinomas.
- Conditions
- Rectal Neoplasms, Adenocarcinoma, Carcinoma
- Trial name
- NEOMETRE (NCT02473094)
- Testing
- Capecitabine, Metformin, Radiotherapy
- Where
- Brazil
- Volunteers
- 3 people
- Sponsor
- University of Campinas, Brazil
Colorectal Cancer
Radiation Therapy and Chemotherapy Followed by Surgery and Combination Chemotherapy in Treating Patients With Rectal Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00021398
- Testing
- fluorouracil, leucovorin calcium, conventional surgery
- Where
- 17 sites in United States
- Volunteers
- 23 people
- Sponsor
- Fox Chase Cancer Center
Locally Advanced Rectal Cancer
A Clinical Study Conducted in Multiple Centers Evaluating Escalating Doses of Veliparib in Combination With Capecitabine and Radiation in Patients With Locally Advanced Rectal Cancer
An open-label, Phase 1b, dose escalation study evaluating the safety and tolerability of the PARP inhibitor Veliparib in combination with capecitabine and radiation in subjects with locally advanced rectal cancer (LARC).
- Trial name
- NCT01589419
- Testing
- veliparib, capecitabine, radiation
- Where
- 6 sites in United States, Australia
- Volunteers
- 32 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Advanced Malignant Neoplasm, Colorectal Cancer
The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey
Collect the real clinical background of advanced colorectal cancer c of China.
- Trial name
- Sprit (NCT01549067)
- Where
- 2 sites in China
- Volunteers
- 3,700 people
- Sponsor
- Chinese Medical Doctor Association
Rectal Neoplasms, Rectal Cancer, Adenocarcinoma
SCRT + Fruquintinib + Tislelizumab + CAPOX Versus SCRT + Tislelizumab + CAPOX as Neoadjuvant Therapy for Locally Advanced Low Rectal Cancer
The goal of this randomized controlled clinical trial is to learn if adding fruquintinib to short-course radiotherapy, tislelizumab, and CAPOX can improve neoadjuvant treatment response and is safe for adults with locally…
- Trial name
- TRIP-FAST (NCT07888309)
- Testing
- Short-Course Radiotherapy, Fruquintinib, Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Ruijin Hospital
Locally Advanced Rectal Cancer
Short-course Radiotherapy Based TNT Combined With PD-1 Inhibitor for Locally Advanced Rectal Cancer
TORCH is a prospective, multicentre, randomized phase II trial. 130 LARC (T3-4/N+M0, distance from anal verge ≤12cm) patients will be treated with total neoadjuvant therapy (TNT) and assigned to Group A and Group B.
- Trial name
- TORCH (NCT04518280)
- Testing
- PD-1 antibody, Capecitabine, Oxaliplatin
- Where
- 3 sites in China
- Volunteers
- 130 people
- Sponsor
- Fudan University
Patients With Metastatic Tumours (Colorectal Cancer, Non-small Lung Cancer, Renal Cell Carcinoma or Sarcoma )
Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours
Although it is usually described as an immunosuppressive modality and not thought of as immunotherapy, there are new preclinical evidences suggesting that high-dose ionizing irradiation (IR) results in direct tumour cell death…
- Trial name
- SABR-PDL1 (NCT02992912)
- Testing
- Anti-PD-L1 antibody atezolizumab, SABR
- Where
- France
- Volunteers
- 138 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Prostate Cancer
Hyaluronic Acid for Hypofractionated Prostate Radiotherapy
The present Phase II study aims to assess the rates of late rectal toxicities of grade ≥ 2 after hypofractionated radiotherapy of prostate cancer of 62 Gy in 20 fractions of 3.1 Gy with an injection of hyaluronic acid (HA) in the…
- Trial name
- RPAH1 (NCT02165020)
- Testing
- Hyaluronic acid (Macrolane VRF 30®, Q-MED)
- Where
- France
- Volunteers
- 36 people
- Sponsor
- Hospices Civils de Lyon
Rectal Neoplasm Malignant
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy
Treatment for Low rectal cancer, especially in patients with regional lymph node metastasis are quite different between Japanese guideline (JSCCR) and western countries' guideline (NCCN, ESMO).
- Trial name
- TELEPHOME (NCT03587480)
- Testing
- TME+LLND, TME+nCRT
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Colorectal Cancer, Metastatic Colorectal Cancer
Abscopal Effect for Metastatic Colorectal Cancer
Patients with colorectal cancer that had metastatic lesions after been treated with definitive surgery or chemoradiotherapy are being asked to participate in this study. 1.
- Conditions
- Colorectal Cancer, Metastatic Colorectal Cancer, Thymalfasin
- Trial name
- NCT02535988
- Testing
- Radiation therapy, Thymalfasin
- Sponsor
- Zhejiang Provincial People's Hospital
Rectal Cancer, Radiotherapy
IMRT Versus 3DCRT for Locally Advanced Rectal Cancer, Prospective Phase II Study.
The goal of this prospective phase II study was to determine whether personalized planning-based nCRT for LARC would indeed decrease small bowel dose, and whether selected plans, specifically prioritizing lower dose to small…
- Conditions
- Rectal Cancer, Radiotherapy, Toxicity Due to Radiotherapy
- Trial name
- NCT06160570
- Testing
- Intensive Modulated Radiation Therapy, 3-Dimension Conformal Radiation Therapy
- Where
- Israel
- Volunteers
- 75 people
- Sponsor
- Rabin Medical Center
Rectal Neoplasms
Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer
This study will assess the complete clinical response (no clinical evidence of remaining disease or recurrence of disease)in rectal cancer that arises within 3 inches of the anal opening after radiation therapy given at the same…
- Trial name
- NCT01613469
- Testing
- 5FU/Leucovorin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Marks, John, M.D.
Rectal Cancer
Colon Neoadjuvant FOLFOXIRI Study
Objective tumour response rate to FOLFOXIRI to pre-operative therapy.
- Trial name
- NCT01941641
- Testing
- neoadjuvant FOLFOXIRI, Capecitabine
- Where
- Hong Kong
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Oncology, Breast Cancer
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further…
- Conditions
- Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer
- Trial name
- MOMENTUM (NCT04075305)
- Testing
- Radiation therapy
- Where
- 18 sites in United States, Australia and 7 more
- Volunteers
- 8,000 people
- Sponsor
- UMC Utrecht